Healthcare provider profile · identity verified

Margaret A Killam, MD

Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, KS · NPI 1043370489

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Margaret A Killam, MD received $33.43 in general payments during 2025 across 2 reported records.

Dexcom, Inc. accounted for 55.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$33.43

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Dexcom, Inc.	Unresolved — no canonical attribution shown	$18.51	55.4%	1	2025
Amgen Inc.	Unresolved — no canonical attribution shown	$14.92	44.6%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$33.43	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Dexcom G6 Transmitter Normalized: dexcom g6 transmitter	Medical Supply	Dexcom, Inc.	$18.51	1	2025
Source payment records 2025-06-10 · Dexcom, Inc. · $18.51 · Open Payments source
OTEZLA Normalized: otezla	Drug	Amgen Inc.	$14.92	1	2025
Source payment records 2025-03-13 · Amgen Inc. · $14.92 · Open Payments source
REPATHA Normalized: repatha	Biological	Amgen Inc.	$14.92	1	2025
Source payment records 2025-03-13 · Amgen Inc. · $14.92 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Amgen Inc. Exact reporting entity; no affiliate inference	2025	PROLIA open payments reported associated product	CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448	Prolia · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1079	269
Amlodipine Besylate	Amlodipine Besylate	673	175
Losartan Potassium	Losartan Potassium	659	166
Hydrochlorothiazide	Hydrochlorothiazide	499	123
Levothyroxine Sodium	Levothyroxine Sodium	484	106
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	441	78
Lisinopril	Lisinopril	387	94
Metformin Hcl Er	Metformin Hcl	356	94
Albuterol Sulfate Hfa	Albuterol Sulfate	354	91
Pantoprazole Sodium	Pantoprazole Sodium	318	75
Omeprazole	Omeprazole	317	78
Fluticasone Propionate	Fluticasone Propionate	308	87
Metoprolol Succinate	Metoprolol Succinate	308	65
Escitalopram Oxalate	Escitalopram Oxalate	243	54
Glipizide Er	Glipizide	236	54
Gabapentin	Gabapentin	228	59
Simvastatin	Simvastatin	227	58
Alendronate Sodium	Alendronate Sodium	221	60
Metformin Hcl	Metformin Hcl	213	57
Tizanidine Hcl	Tizanidine Hcl	204	54
Potassium Chloride	Potassium Chloride	203	50
Zolpidem Tartrate	Zolpidem Tartrate	190	40
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	186	50
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	174	49
Pravastatin Sodium	Pravastatin Sodium	172	42
Trazodone Hcl	Trazodone Hcl	170	35
Alprazolam	Alprazolam	169	42
Famotidine	Famotidine	152	41
Jardiance	Empagliflozin	142	31
Furosemide	Furosemide	126	34
Ozempic	Semaglutide	124	29
Citalopram Hbr	Citalopram Hydrobromide	120	28
Allopurinol	Allopurinol	119	28
Meloxicam	Meloxicam	118	30
Oxybutynin Chloride Er	Oxybutynin Chloride	116	17
Metoprolol Tartrate	Metoprolol Tartrate	112	26
Duloxetine Hcl	Duloxetine Hcl	110	22
Sertraline Hcl	Sertraline Hcl	110	23
Montelukast Sodium	Montelukast Sodium	105	27
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	105	22
Venlafaxine Hcl Er	Venlafaxine Hcl	102	19
Rosuvastatin Calcium	Rosuvastatin Calcium	100	30
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	98	23
Ibuprofen	Ibuprofen	97	29
Carvedilol	Carvedilol	90	21
Donepezil Hcl	Donepezil Hcl	88	14
Atenolol	Atenolol	83	21
Januvia	Sitagliptin Phosphate	81	17
Lovastatin	Lovastatin	81	18
Tramadol Hcl	Tramadol Hcl	78	30
Tolterodine Tartrate Er	Tolterodine Tartrate	77	19
Paroxetine Hcl	Paroxetine Hcl	75	suppressed
Buspirone Hcl	Buspirone Hcl	72	16
Bupropion Xl	Bupropion Hcl	70	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	70	17
Tamsulosin Hcl	Tamsulosin Hcl	70	20
Clonazepam	Clonazepam	68	14
Fluoxetine Hcl	Fluoxetine Hcl	66	13
Pregabalin	Pregabalin	62	15
Clopidogrel	Clopidogrel Bisulfate	61	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	61	18
Glimepiride	Glimepiride	54	14
Lorazepam	Lorazepam	53	11
Benazepril Hcl	Benazepril Hcl	52	suppressed
Amoxicillin	Amoxicillin	51	45
Eliquis	Apixaban	51	12
Risperidone	Risperidone	51	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	51	27
Ezetimibe	Ezetimibe	48	15
Valacyclovir	Valacyclovir Hcl	47	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	46	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	44	18
Ropinirole Hcl	Ropinirole Hcl	42	14
Amitriptyline Hcl	Amitriptyline Hcl	41	11
Sumatriptan Succinate	Sumatriptan Succinate	40	suppressed
Prednisone	Prednisone	39	19
Diclofenac Sodium	Diclofenac Sodium	38	suppressed
Trulicity	Dulaglutide	37	suppressed
Morphine Sulfate Er	Morphine Sulfate	36	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	35	13
Desmopressin Acetate	Desmopressin Acetate	34	suppressed
Estradiol	Estradiol	34	suppressed
Myrbetriq	Mirabegron	34	suppressed
Glipizide	Glipizide	33	suppressed
Fluconazole	Fluconazole	32	18
Nystatin	Nystatin	32	17
Varenicline Tartrate	Varenicline Tartrate	32	12
Hydralazine Hcl	Hydralazine Hcl	31	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	14
Baclofen	Baclofen	30	suppressed
Naproxen	Naproxen	30	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	30	suppressed
Ondansetron Hcl	Ondansetron Hcl	30	15
Oxycodone Hcl	Oxycodone Hcl	29	16
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	28	suppressed
Methylprednisolone	Methylprednisolone	28	26
Mounjaro	Tirzepatide	28	suppressed
Synthroid	Levothyroxine Sodium	28	suppressed
Warfarin Sodium	Warfarin Sodium	28	suppressed
Celecoxib	Celecoxib	27	suppressed
Cephalexin	Cephalexin	27	22
Lubiprostone	Lubiprostone	27	suppressed
Klor-Con M20	Potassium Chloride	26	suppressed
Diazepam	Diazepam	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	22
Mirtazapine	Mirtazapine	24	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	23	14
Finasteride	Finasteride	23	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	23	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Linzess	Linaclotide	22	suppressed
Ibu	Ibuprofen	21	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	21	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	21	suppressed
Solifenacin Succinate	Solifenacin Succinate	21	suppressed
Bumetanide	Bumetanide	20	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Fenofibrate	Fenofibrate,micronized	20	suppressed
Symbicort	Budesonide/Formoterol Fumarate	20	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	19	suppressed
Tiadylt Er	Diltiazem Hcl	19	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	19	14
Calcium Acetate	Calcium Acetate	18	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	18	suppressed
Meclizine Hcl	Meclizine Hcl	18	suppressed
Methotrexate	Methotrexate Sodium	18	suppressed
Primidone	Primidone	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Klayesta	Nystatin	17	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	16	suppressed
Levemir Flexpen	Insulin Detemir	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Repatha Syringe	Evolocumab	16	suppressed
Azithromycin	Azithromycin	15	13
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Arnuity Ellipta	Fluticasone Furoate	14	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	14	suppressed
Fentanyl	Fentanyl	14	suppressed
Fesoterodine Fumarate Er	Fesoterodine Fumarate	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Premarin	Estrogens, Conjugated	13	suppressed
Prolia	Denosumab	13	suppressed
Tiotropium Bromide	Tiotropium Bromide	13	suppressed
Valsartan	Valsartan	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Amlodipine-Atorvastatin	Amlodipine/Atorvastatin	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$33.43 · 2 records	Dexcom, Inc.	Dexcom G6 Transmitter, OTEZLA, REPATHA	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error